Koers Bayer Aktiengesellschaft Other OTC
Aandelen
BAYRY
US0727303028
Farmaceutische producten
Omzet 2024 * | 47,17 mld. 51,15 mld. | Omzet 2025 * | 47,88 mld. 51,92 mld. | Marktkapitalisatie | 28,15 mld. 30,52 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 2,36 mld. 2,56 mld. | Nettowinst (verlies) 2025 * | 3,18 mld. 3,45 mld. | EV/omzet 2024 * | 1,28 x |
Nettoschuld 2024 * | 32,4 mld. 35,14 mld. | Nettoschuld 2025 * | 30,17 mld. 32,72 mld. | EV/omzet 2025 * | 1,22 x |
K/w-verhouding 2024 * |
12,4
x | K/w-verhouding 2025 * |
8,78
x | Werknemers | - |
Dividendrendement 2024 * |
0,38% | Dividendrendement 2025 * |
0,78% | Vrij verhandelbaar | 99,97% |
Recentste transcriptie over Bayer Aktiengesellschaft
Managers | Titel | Leeftijd | Van |
---|---|---|---|
William Anderson
CEO | Chief Executive Officer | 57 | 01-04-23 |
Director of Finance/CFO | 55 | 26-04-18 | |
Bijoy Sagar
CTO | Chief Tech/Sci/R&D Officer | 55 | 01-04-20 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Colleen Goggins
BRD | Director/Board Member | 68 | 01-04-17 |
Alberto Weisser
BRD | Director/Board Member | 67 | 01-04-21 |
Paul Achleitner
BRD | Director/Board Member | 67 | 01-04-02 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+32,36% | 694 mld. | |
+30,07% | 593 mld. | |
-1,60% | 371 mld. | |
+20,07% | 331 mld. | |
+6,04% | 290 mld. | |
+14,49% | 239 mld. | |
+10,45% | 209 mld. | |
-2,94% | 209 mld. | |
+9,27% | 169 mld. |